Navigation Links
New Data Published in The Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Date:11/23/2007

Protection Sustained During the First Two Years of Life

PHILADELPHIA, Nov. 23 /PRNewswire-FirstCall/ -- New data from a large European clinical trial published today in The Lancet show ROTARIX(R), GlaxoSmithKline's (NYSE: GSK) oral rotavirus candidate vaccine to prevent rotavirus gastroenteritis, provides protection against the five most commonly circulating rotavirus types around the world and in the United States (U.S.). The GSK candidate vaccine, if approved by the U.S. Food and Drug Administration (FDA), would enable completion of the rotavirus vaccination series by four months of age. Severe, dehydrating gastroenteritis occurs most commonly among children aged three to 35 months. Of children in the U.S. hospitalized with rotavirus, approximately one in five are younger than six months old.

Results from this multi-center, randomized, double-blind, placebo- controlled phase III clinical trial involving almost 4,000 European infants (candidate rotavirus vaccine n=2,572; placebo n=1,302) demonstrated that two doses of ROTARIX provided highly effective and sustained protection through two consecutive rotavirus seasons (approximately two years of age). The data show that, through two rotavirus seasons, the vaccine was highly efficacious against rotavirus hospitalizations (96%), severe rotavirus gastroenteritis (90%) and against rotavirus gastroenteritis of any severity (79%). Specifically, significant protection was demonstrated against severe rotavirus gastroenteritis caused by types G1 (96%), G2 (86%), G3 (94%), G4 (95%), and G9 (85%), the most commonly circulating rotavirus types around the world and in the United States.

"The candidate vaccine contains a live, weakened form of natural human rotavirus derived from the most common human rotavirus strain with the goal of offering protection against the most commonly circulating and emerging rotavirus serotypes by mimicking the protective effects of natural human rotavirus infection," said David I. Bernstein, MD, MA, Director, Infectious Diseases; Gamble Program at Cincinnati Children's Hospital Medical Center. "These data are important because they confirm that immunization with two doses of the rotavirus candidate vaccine could provide broad protection against rotavirus gastroenteritis caused by emerging types in addition to those that are already commonly circulating."

In an additional analysis, protection against severe rotavirus gastroenteritis in the period between dose one and dose two was observed to be 90%. The protection offered by the two-dose schedule of this rotavirus vaccine observed as early as after dose one is particularly relevant as severe dehydrating rotavirus gastroenteritis can occur in infants as young as three months of age.

Since rotavirus is highly infectious, the spread of the disease may be difficult to control. Vaccination against rotavirus is recognized as the best measure to protect children against rotavirus disease and has been shown to be highly effective in preventing the disease.

The CDC Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) recommend that infants receive routine vaccination with the rotavirus vaccine currently licensed by the FDA at two, four, and six months of age in order to prevent rotavirus gastroenteritis.

GSK's Biologics License Application (BLA) for the candidate rotavirus vaccine is currently under review by the U.S. Food and Drug Administration (FDA). It is proposed that the vaccine would be given in two oral doses beginning at six weeks of age and completed by 24 weeks of age, with a minimum four-week interval between the doses. If approved, the vaccine could be integrated into the current vaccine schedule at the two and four month immunization visits.

About ROTARIX(R)

The GSK rotavirus candidate vaccine is a live-attenuated oral rotavirus vaccine licensed in more than 100 countries around the world. The vaccine is designed to prevent rotavirus gastroenteritis by mimicking the protective effects of natural human rotavirus infection. Studies have shown that natural rotavirus infection provides significant protection from moderate to severe disease, regardless of rotavirus strain. In clinical trials conducted in support of US licensure, the most common solicited adverse reactions were fussiness, runny nose, fever, loss of appetite, and vomiting. Adverse reactions among recipients of ROTARIX and placebo occurred at similar rates.

About Rotavirus

Rotavirus infects virtually every child worldwide by age five and is the leading cause of severe acute gastroenteritis in infants and young children in the U.S. and worldwide. Severe diarrhea and dehydration occur primarily from as young as three months of age. In the U.S. each year, 2.7 million children younger than five years of age suffer from rotavirus disease, resulting in 410,000 clinic visits and up to 272,000 emergency room visits. In addition, between 55,000 and 70,000 children are hospitalized and 20-60 die each year. In the U.S., the rotavirus season begins in the southwest during November- December and spreads to the northeast by April-May.

GlaxoSmithKline: A Leader in Vaccines

GlaxoSmithKline, with U.S. operations in Philadelphia, PA, and Research Triangle Park, NC, is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted.

GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world - an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children from up to six diseases in one vaccine.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2006.

Inquiries:

US Media Inquiries Jeff +1 919 483 2839

McLaughlin

UK Media Inquiries Alice Hunt +44 20 8047 5502

US Analyst/Investor Inquiries Frank Murdolo +1 215 751 7002

Tom Curry +1 215 751 5419

References:

1. Vesikari T., et al, Human rotavirus vaccine is highly efficacious

against rotavirus gastroenteritis during the first two years of life

in European infants: results of a randomised double-blind controlled

study. The Lancet; 2007

2. American Academy of Pediatrics. Policy Statement: Prevention of

Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine.

3. Centers for Disease Control and Prevention. Prevention of Rotavirus

Gastroenteritis Among Infants and Children. MMWR. 2006; 55(RR12);

1-13.

4. Centers for Disease Control and Prevention. The Pink Book - Rotavirus

Chapter.

5. Dennehy PH. Transmission of rotavirus and other enteric pathogens in

the home. Pediatric Infectious Disease Journal 2000; 19 (10 Suppl):

S 103-5

6. Centers for Disease Control and Prevention. Rotavirus Disease: What

You Need to Know.

7. Centers for Disease Control and Prevention. Recommended Immunization

Schedule for Ages 0-6 Years - United States 2007.

8. Green KY, et al. Homotypic and Heterotypic Epitope-Specific Antibody

Responses in Adult and Infant Rotavirus Vaccines: Implications for

Vaccine Development. The Journal of Infectious Diseases.

1990;161:667-679.

9. GSK data on file.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):